Sp395
THE PROMISE OF NATURAL LANGUAGE PROCESSING IN CLINICAL PRACTICE
Date
May 7, 2023
Explore related products in the following collection:
Society: AGA
Over the past decade, big data and artificial intelligence (AI) have become standard concepts in digestive disease research, both as individual tools and applied together. Artificial intelligence algorithms and large datasets are now applied to everything from unraveling the pathophysiology of disease mechanisms in model systems to precisely selecting the most appropriate treatment courses for patients. Speakers in this session will provide examples where big data and artificial intelligence have successfully advanced science and patient care, where these tools have failed to live up to expectations, and provide perspective on overcoming obstacles to further developing the tools. The session will focus on three thematic areas where AI and big data impact GI: clinical databases and natural language processing, biological datasets, and imaging.
Over the past decade, big data and artificial intelligence (AI) have become standard concepts in digestive disease research, both as individual tools and applied together. Artificial intelligence algorithms and large datasets are now applied to everything from unraveling the pathophysiology of disease mechanisms in model systems to precisely selecting the most appropriate treatment courses for patients. Speakers in this session will provide examples where big data and artificial intelligence have successfully advanced science and patient care, where these tools have failed to live up to expectations, and provide perspective on overcoming obstacles to further developing the tools. The session will focus on three thematic areas where AI and big data impact GI: clinical databases and natural language processing, biological datasets, and imaging.
Presenter
University of Michigan
Tracks
Related Products
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
AUTOMATED DIGITAL ULCER QUANTITATION IN COLONOSCOPY IS BETTER ASSOCIATED WITH CLINICAL REMISSION THAN CONVENTIONAL ENDOSCOPIC SCORING IN CROHN’S DISEASE
BACKGROUND: Anti-granulocyte macrophage-colony stimulating factor autoantibodies (anti-GM-CSF) have been associated with development of Crohn’s disease (CD) and complications at time of diagnosis. There are limited data on anti-GM-CSF as a prognostic biomarker in CD…
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
ENCAPSULATED MICROBIOTA TRANSPLANT THERAPY IMPROVES PARTIAL MAYO SCORES IN ULCERATIVE COLITIS AND INDUCES RAPID ENGRAFTMENT COMPARED TO PLACEBO CONTROL
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
